Journal ArticleDOI
The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer
Hartwig Riediger,Tobias Keck,Ulrich F. Wellner,Axel zur Hausen,Ulrich Adam,Ulrich T. Hopt,Frank Makowiec +6 more
Reads0
Chats0
TLDR
The routine estimation of the LN ratio may be helpful not only for the individual prediction of prognosis but also for the indication of adjuvant therapy and herein related outcome and therapy studies.About:
This article is published in Journal of Gastrointestinal Surgery.The article was published on 2009-05-06. It has received 311 citations till now. The article focuses on the topics: Resection margin.read more
Citations
More filters
Book ChapterDOI
Pathology and Genetics
TL;DR: Local aggressiveness consists in the invasion of contiguous structures and organs (spleen, stomach, left adrenal gland, colon, and peritoneum), whereas distant metastases can occur in liver, lungs, adrenals, kidneys, bones, brain, and skin.
Journal ArticleDOI
Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS).
Johanna A. M. G. Tol,Dirk J. Gouma,Claudio Bassi,Christos Dervenis,Marco Montorsi,Mustapha Adham,Åke Andrén-Sandberg,Horacio J. Asbun,Maximilian Bockhorn,Markus W. Büchler,Kevin C. Conlon,Laureano Fernández-Cruz,Abe Fingerhut,Abe Fingerhut,Helmut Friess,Werner Hartwig,Jakob R. Izbicki,Keith D. Lillemoe,Miroslav Milicevic,John P. Neoptolemos,Shailesh V. Shrikhande,Charles M. Vollmer,Charles J. Yeo,Richard Charnley +23 more
TL;DR: Standard lymphadenectomy for pancreatoduodenectomy should strive to resect Ln stations no. 5, 6, 8a, 12b1,12b2, 12c, 13a, 13b, 14a, 14b, 17a, and 17b, for cancers of the body and tail of the pancreas, removal of stations 10, 11, and 18 is standard.
Journal ArticleDOI
Pancreatic cancer surgery in the new millennium: better prediction of outcome.
Werner Hartwig,Thilo Hackert,Ulf Hinz,Alexander Gluth,Frank Bergmann,Oliver Strobel,Markus W. Büchler,Jens Werner +7 more
TL;DR: A newly defined prognostic profiling including the revised R1-definition discriminates survival of patients with resectable pancreatic adenocarcinoma better than the AJCC staging system, and may be of particular relevance for patient-adjusted therapy in the heterogeneous group of AJCC stage II tumors.
Journal ArticleDOI
Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma.
Peter J. Allen,Deborah Kuk,Carlos Fernandez-del Castillo,Olca Basturk,Christopher L. Wolfgang,John L. Cameron,Keith D. Lillemoe,Cristina R. Ferrone,Vicente Morales-Oyarvide,Jin He,Matthew J. Weiss,Ralph H. Hruban,Mithat Gonen,David S. Klimstra,Mari Mino-Kenudson +14 more
TL;DR: The proposed 8th edition changes for T and N classification were statistically valid and may allow a more reproducible system of T staging, which stratifies patients more evenly across stages without sacrificing prognostic accuracy.
Journal ArticleDOI
Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up
TL;DR: In Europe, cancer of the pancreas is the seventh most frequent cancer, accounting for some 2.8% of cancer in men and 3.2% in women, and has a dismal prognosis.
References
More filters
Journal ArticleDOI
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle,Stefan Post,Peter Neuhaus,Klaus Gellert,Jan M. Langrehr,Karsten Ridwelski,Harald Schramm,J. Fahlke,Carl Zuelke,Christof Burkart,Klaus Gutberlet,E. Kettner,Harald Schmalenberg,Karin Weigang-Koehler,Wolf O. Bechstein,Marco Niedergethmann,Ingo G.H. Schmidt-Wolf,Lars Roll,Bernd Doerken,Hanno Riess +19 more
TL;DR: The results support the use of gemcitabine as adjuvant chemotherapy in resectable carcinoma of the pancreas by significantly delayed the development of recurrent disease after complete resection of pancreatic cancer compared with observation alone.
Journal ArticleDOI
Resected adenocarcinoma of the pancreas— 616 patients: Results, outcomes, and prognostic indicators
Taylor A. Sohn,Charles J. Yeo,John L. Cameron,Leonidas G. Koniaris,Sunjay Kaushal,Ross A. Abrams,Patricia K. Sauter,JoAnn Coleman,Ralph H. Hruban,Keith D. Lillemoe +9 more
TL;DR: Factors influencing long-term survival after resection in patients with adenocarcinoma of the head, neck, uncinate process, body, or tail of the pancreas are examined to decrease the independent significance of tumor location and nodal status.
Journal ArticleDOI
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience.
Jordan M. Winter,John L. Cameron,Kurtis A. Campbell,Meghan A. Arnold,David C. Chang,Jo Ann Coleman,Mary Hodgin,Patricia K. Sauter,Ralph H. Hruban,Taylor S. Riall,Richard D. Schulick,Michael A. Choti,Keith D. Lillemoe,Charles J. Yeo +13 more
TL;DR: Patients who have cancers with favorable pathological features have a statistically significant improved long-term survival, and pathological factors having a significant impact on survival included tumor diameter, resection margin status, lymph node status, and histologic grade.
Journal ArticleDOI
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
John P. Neoptolemos,Janet A. Dunn,Deborah D. Stocken,J. Almond,Karl-Heinrich Link,H. G. Beger,Claudio Bassi,Massimo Falconi,Paolo Pederzoli,Christos Dervenis,Laureano Fernández-Cruz,François Lacaine,Akos F. Pap,David Spooner,David J. Kerr,Helmut Friess,Markus W. Büchler +16 more
TL;DR: This study showed no survival benefit for chemoradiotherapy but revealed a potential benefit for adjuvant chemotherapy, justifying further randomised controlled trials of adjUvant chemotherapy in pancreatic cancer.
Journal ArticleDOI
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.
Charles J. Yeo,John L. Cameron,Keith D. Lillemoe,Taylor A. Sohn,Kurtis A. Campbell,Patricia K. Sauter,Jo Ann Coleman,Ross A. Abrams,Ralph H. Hruban +8 more
TL;DR: The data to date fail to indicate that a survival benefit is derived from the addition of a distal gastrectomy and retroperitoneal lymphadenectomy to a pylorus-preserving pancreaticoduodenectomy.
Related Papers (5)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Helmut Oettle,Stefan Post,Peter Neuhaus,Klaus Gellert,Jan M. Langrehr,Karsten Ridwelski,Harald Schramm,J. Fahlke,Carl Zuelke,Christof Burkart,Klaus Gutberlet,E. Kettner,Harald Schmalenberg,Karin Weigang-Koehler,Wolf O. Bechstein,Marco Niedergethmann,Ingo G.H. Schmidt-Wolf,Lars Roll,Bernd Doerken,Hanno Riess +19 more